VIDEO: CAR T-cell therapy "highly effective" for heavily pretreated patients with ALL
Click Here to Manage Email Alerts
In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the results of a phase 2 study that evaluated a new CAR T-cell therapy for adult patients with ALL.
A study of 71 patients with relapsed/refractory acute lymphoblastic leukemia showed that 71% of patients achieved complete remission. Heavily pretreated ALL patients received a single dose of KTE-X19 after conditioning chemotherapy, according to the study report.
"To me that's just incredible, because for adult ALL ... they’re almost always going to pass very quickly," Byrd said. "Though there was considerable toxicity ... it was highly effective," he said.
Collapse
Shah B, et all. Abstract 7002. Presented at: ASCO 2021; June 4-8, 2021 (virtual meeting).
Click Here to Manage Email Alerts